Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02134015
Title Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Daiichi Sankyo Inc., Parexel
Indications

lung non-small cell carcinoma

Therapies

Erlotinib

Erlotinib + Patritumab

Age Groups: adult
Covered Countries USA | ITA | ESP | DEU | CAN | BEL


No variant requirements are available.